Cencora, Inc. (COR) Stock Competitors & Peer Comparison
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $296.57 | -1.89% | 57.7B | 17.79 | $16.67 | +0.78% |
| MCK | $796.35 | -0.87% | 93.3B | 20.34 | $39.15 | +0.41% |
| CAH | $224.94 | -2.25% | 52.7B | 21.57 | $10.43 | +0.90% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $87.16 | +0.29% | 9.9B | 16.96 | $5.14 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| GRDN | $39.97 | +0.76% | 2.5B | 35.05 | $1.14 | N/A |
| PBH | $48.36 | +2.48% | 2.3B | 11.01 | $4.39 | N/A |
| ACH | $3.63 | +0.69% | 277.2M | 5.32 | $0.68 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
COR vs MCK Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, MCK has a market cap of 93.3B. Regarding current trading prices, COR is priced at $296.57, while MCK trades at $796.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas MCK's P/E ratio is 20.34. In terms of profitability, COR's ROE is +1.16%, compared to MCK's ROE of -2.65%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here
COR vs CAH Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, CAH has a market cap of 52.7B. Regarding current trading prices, COR is priced at $296.57, while CAH trades at $224.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas CAH's P/E ratio is 21.57. In terms of profitability, COR's ROE is +1.16%, compared to CAH's ROE of -0.56%. Regarding short-term risk, COR is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CAH's competition here
COR vs ABC Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $296.57, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.16%, compared to ABC's ROE of +1.15%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
COR vs HSIC Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, HSIC has a market cap of 9.9B. Regarding current trading prices, COR is priced at $296.57, while HSIC trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas HSIC's P/E ratio is 16.96. In terms of profitability, COR's ROE is +1.16%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
COR vs PDCO Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $296.57, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.16%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
COR vs GRDN Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, GRDN has a market cap of 2.5B. Regarding current trading prices, COR is priced at $296.57, while GRDN trades at $39.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas GRDN's P/E ratio is 35.05. In terms of profitability, COR's ROE is +1.16%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GRDN's competition here
COR vs PBH Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, COR is priced at $296.57, while PBH trades at $48.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas PBH's P/E ratio is 11.01. In terms of profitability, COR's ROE is +1.16%, compared to PBH's ROE of +0.10%. Regarding short-term risk, COR is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check PBH's competition here
COR vs ACH Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, ACH has a market cap of 277.2M. Regarding current trading prices, COR is priced at $296.57, while ACH trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas ACH's P/E ratio is 5.32. In terms of profitability, COR's ROE is +1.16%, compared to ACH's ROE of +2.65%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
COR vs OMI Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $296.57, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.16%, compared to OMI's ROE of +2.65%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
COR vs HX Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $296.57, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.16%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
COR vs WGRX Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, WGRX has a market cap of 7.1M. Regarding current trading prices, COR is priced at $296.57, while WGRX trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas WGRX's P/E ratio is -0.27. In terms of profitability, COR's ROE is +1.16%, compared to WGRX's ROE of +15.45%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
COR vs ZYXI Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $296.57, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.16%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
COR vs SNYR Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, SNYR has a market cap of 2.1M. Regarding current trading prices, COR is priced at $296.57, while SNYR trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas SNYR's P/E ratio is -0.14. In terms of profitability, COR's ROE is +1.16%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
COR vs ZSTK Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, ZSTK has a market cap of 2M. Regarding current trading prices, COR is priced at $296.57, while ZSTK trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas ZSTK's P/E ratio is -0.04. In terms of profitability, COR's ROE is +1.16%, compared to ZSTK's ROE of -3.53%. Regarding short-term risk, COR is less volatile compared to ZSTK. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ZSTK's competition here
COR vs RDGT Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, RDGT has a market cap of 1.3M. Regarding current trading prices, COR is priced at $296.57, while RDGT trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas RDGT's P/E ratio is -0.03. In terms of profitability, COR's ROE is +1.16%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
COR vs CVET Comparison July 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 57.7B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $296.57, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.79, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.16%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here